S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
Log in
NASDAQ:TNDM

Tandem Diabetes Care Stock Forecast, Price & News

$98.62
+4.18 (+4.43 %)
(As of 01/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$93.63
Now: $98.62
$101.00
50-Day Range
$86.40
MA: $93.20
$97.59
52-Week Range
$43.69
Now: $98.62
$123.74
Volume1.16 million shs
Average Volume735,305 shs
Market Capitalization$6.01 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.31
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin delivery system with Basal-IQ Technology; t:slim X2 with control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump and supported blood glucose meters for users, their caregivers, and their healthcare providers. Its products in development include t:sport insulin delivery system; and connected (mobile) health offerings. Further, the company offers Sugarmate, a mobile app for people with diabetes who use insulin. Tandem Diabetes Care, Inc. has a development and commercialization agreement with Dexcom, Inc. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was founded in 2006 and is headquartered in San Diego, California.
Tandem Diabetes Care logo

MarketRank

Overall MarketRank

1.42 out of 5 stars

Medical Sector

522nd out of 1,925 stocks

Surgical & Medical Instruments Industry

50th out of 169 stocks

Analyst Opinion: 2.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TNDM
CUSIPN/A
Phone858-366-6900
Employees1,043

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$362.30 million
Book Value$3.30 per share

Profitability

Net Income$-24,750,000.00

Miscellaneous

Market Cap$6.01 billion
Next Earnings Date2/24/2021 (Confirmed)
OptionableOptionable
$98.62
+4.18 (+4.43 %)
(As of 01/22/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TNDM News and Ratings via Email

Sign-up to receive the latest news and ratings for TNDM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Tandem Diabetes Care (NASDAQ:TNDM) Frequently Asked Questions

How has Tandem Diabetes Care's stock been impacted by COVID-19 (Coronavirus)?

Tandem Diabetes Care's stock was trading at $66.33 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, TNDM shares have increased by 48.7% and is now trading at $98.62.
View which stocks have been most impacted by COVID-19
.

Is Tandem Diabetes Care a buy right now?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tandem Diabetes Care in the last twelve months. There are currently 5 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Tandem Diabetes Care stock.
View analyst ratings for Tandem Diabetes Care
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Tandem Diabetes Care?

Wall Street analysts have given Tandem Diabetes Care a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Tandem Diabetes Care wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Tandem Diabetes Care's CEO?

1,448 employees have rated Tandem Diabetes Care CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among Tandem Diabetes Care's employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Tandem Diabetes Care's next earnings date?

Tandem Diabetes Care is scheduled to release its next quarterly earnings announcement on Wednesday, February 24th 2021.
View our earnings forecast for Tandem Diabetes Care
.

How can I listen to Tandem Diabetes Care's earnings call?

Tandem Diabetes Care will be holding an earnings conference call on Wednesday, February 24th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Tandem Diabetes Care's earnings last quarter?

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) posted its quarterly earnings results on Thursday, November, 5th. The medical device company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.08) by $0.07. The medical device company earned $123.60 million during the quarter, compared to analyst estimates of $115.16 million. Tandem Diabetes Care had a negative net margin of 11.10% and a negative return on equity of 10.98%. The business's revenue was up 30.6% on a year-over-year basis. During the same period in the prior year, the company posted ($0.09) earnings per share.
View Tandem Diabetes Care's earnings history
.

When did Tandem Diabetes Care's stock split? How did Tandem Diabetes Care's stock split work?

Shares of Tandem Diabetes Care reverse split before market open on Tuesday, October 10th 2017. The 1-10 reverse split was announced on Monday, October 9th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, October 9th 2017. An investor that had 100 shares of Tandem Diabetes Care stock prior to the reverse split would have 10 shares after the split.

What guidance has Tandem Diabetes Care issued on next quarter's earnings?

Tandem Diabetes Care issued an update on its FY 2020 After-Hours earnings guidance on Thursday, November, 5th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $465-475 million, compared to the consensus revenue estimate of $462.16 million.

What price target have analysts set for TNDM?

14 brokerages have issued 12 month target prices for Tandem Diabetes Care's stock. Their forecasts range from $75.00 to $140.00. On average, they expect Tandem Diabetes Care's stock price to reach $114.57 in the next twelve months. This suggests a possible upside of 16.2% from the stock's current price.
View analysts' price targets for Tandem Diabetes Care
or view Wall Street analyst' top-rated stocks.

Are investors shorting Tandem Diabetes Care?

Tandem Diabetes Care saw a increase in short interest in the month of December. As of December 31st, there was short interest totaling 4,360,000 shares, an increase of 38.9% from the December 15th total of 3,140,000 shares. Based on an average daily volume of 813,200 shares, the short-interest ratio is presently 5.4 days.
View Tandem Diabetes Care's Short Interest
.

Who are some of Tandem Diabetes Care's key competitors?

What other stocks do shareholders of Tandem Diabetes Care own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tandem Diabetes Care investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Micron Technology (MU), DexCom (DXCM), Netflix (NFLX), Square (SQ), Roku (ROKU), Lululemon Athletica (LULU) and PayPal (PYPL).

Who are Tandem Diabetes Care's key executives?

Tandem Diabetes Care's management team includes the following people:
  • Mr. John F. Sheridan, Pres, CEO & Director (Age 65, Pay $1.24M)
  • Ms. Leigh A. Vosseller, Exec. VP, CFO & Treasurer (Age 47, Pay $769.82k)
  • Ms. Susan M. Morrison, Exec. VP & Chief Admin. Officer (Age 41, Pay $768.61k)
  • Mr. David B. Berger, Exec. VP, Chief Legal & Compliance Officer and Corp. Sec. (Age 50, Pay $769.25k)
  • Mr. Brian B. Hansen, Exec. VP & Chief Commercial Officer (Age 52, Pay $778.26k)
  • Mr. Jim Leal, Sr. VP of Operations
  • Mr. Manuel Jaime, Sr. VP of Technology & Digital Health
  • Mr. Ross Sylvia, VP of Marketing
  • Ms. Elizabeth A. Gasser, Exec. VP of Strategy & Corp. Devel. (Age 44)
  • Mr. Tom Fox, Sr. VP of HR & Organizational Devel.

What is Tandem Diabetes Care's stock symbol?

Tandem Diabetes Care trades on the NASDAQ under the ticker symbol "TNDM."

Who are Tandem Diabetes Care's major shareholders?

Tandem Diabetes Care's stock is owned by many different institutional and retail investors. Top institutional shareholders include Ardevora Asset Management LLP (0.90%), Columbus Circle Investors (0.51%), Frontier Capital Management Co. LLC (0.19%), Candriam Luxembourg S.C.A. (0.09%), Polianta Ltd (0.02%) and First Hawaiian Bank (0.01%). Company insiders that own Tandem Diabetes Care stock include Brian B Hansen, Christopher J Twomey, David B Berger, Dick Allen, Douglas A Roeder, Edward L Cahill, Howard E Greene Jr, John F Sheridan, Kim D Blickenstaff, Leigh Vosseller, Rebecca B Robertson and Susan Morrison.
View institutional ownership trends for Tandem Diabetes Care
.

Which major investors are selling Tandem Diabetes Care stock?

TNDM stock was sold by a variety of institutional investors in the last quarter, including Columbus Circle Investors, Frontier Capital Management Co. LLC, Ardevora Asset Management LLP, First Hawaiian Bank, and TRUE Private Wealth Advisors. Company insiders that have sold Tandem Diabetes Care company stock in the last year include Brian B Hansen, Christopher J Twomey, David B Berger, Dick Allen, John F Sheridan, Kim D Blickenstaff, Leigh Vosseller, Rebecca B Robertson, and Susan Morrison.
View insider buying and selling activity for Tandem Diabetes Care
or view top insider-selling stocks.

Which major investors are buying Tandem Diabetes Care stock?

TNDM stock was bought by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Kestra Advisory Services LLC, and Polianta Ltd.
View insider buying and selling activity for Tandem Diabetes Care
or or view top insider-buying stocks.

How do I buy shares of Tandem Diabetes Care?

Shares of TNDM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Tandem Diabetes Care's stock price today?

One share of TNDM stock can currently be purchased for approximately $98.62.

How big of a company is Tandem Diabetes Care?

Tandem Diabetes Care has a market capitalization of $6.01 billion and generates $362.30 million in revenue each year. The medical device company earns $-24,750,000.00 in net income (profit) each year or ($0.22) on an earnings per share basis. Tandem Diabetes Care employs 1,043 workers across the globe.

What is Tandem Diabetes Care's official website?

The official website for Tandem Diabetes Care is www.tandemdiabetes.com.

How can I contact Tandem Diabetes Care?

Tandem Diabetes Care's mailing address is 11075 ROSELLE STREET, San Diego CA, 92121. The medical device company can be reached via phone at 858-366-6900 or via email at [email protected]

This page was last updated on 1/24/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.